Funding for this research was provided by:
Actelion Pharmaceuticals (No number)
Text and Data Mining valid from 2019-09-05
Received: 12 June 2019
Accepted: 16 August 2019
First Online: 5 September 2019
Ethics approval and consent to participate
: All participants gave informed consent, and the study was approved by the Wales Research Ethics Committee 5 Bangor (REC Ref. 16/WA/0129), IRAS ID: 192163.
: Consent for publication was obtained from participant 005.
: Dr. Donald has received honoraria for speaking and consulted on advisory boards with Sanofi and Oxyrane; Professor Hughes has received honoraria for speaking and advisory boards from Sanofi and Takeda; Dr. Davies is employed by Aparito and has shares with Aparito, she has offered consultancy with Prevail, Oxyrane, Lysogene and Amicus; Niamh Finnegan has received honoraria from Takeda, Amicus, Biomarin and Sanofi Genzyme; Tanya Collins-Histed has received honoraria and travel and research grants from Prevail, Oxyrane and Shire.